TY - JOUR T1 - Transcriptomic Signaling Pathways involved in a naturalistic model of Inflammation-related Depression and its remission JF - medRxiv DO - 10.1101/2020.09.21.20196592 SP - 2020.09.21.20196592 AU - Marie-Pierre Moisan AU - Aline Foury AU - Sandra Dexpert AU - Steve W Cole AU - Cédric Beau AU - Damien Forestier AU - Patrick Ledaguenel AU - Eric Magne AU - Lucile Capuron Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/23/2020.09.21.20196592.abstract N2 - This study aimed at identifying molecular biomarkers of inflammation-related depression in order to improve diagnosis and treatment. We performed whole-genome expression profiling from peripheral blood in a naturalistic model of inflammation-associated major depressive disorder (MDD) represented by comorbid depression in obese patients. We took advantage of the marked reduction of depressive symptoms and inflammation following bariatric surgery to test the robustness of the identified biomarkers. Depression was assessed during a clinical interview using Mini-International Neuropsychiatric Interview and the 10-item, clinician administered, Montgomery-Asberg Depression Rating Scale. From a cohort of 100 massively obese patients we selected 33 of them for transcriptomic analysis. Twenty-four of them were again analyzed 4-12 months after bariatric surgery. We conducted differential gene expression analyses before and after surgery in unmedicated MDD and non-depressed obese subjects. We found that TP53 (Tumor Protein 53), GR (Glucocorticoid Receptor) and NFκB (Nuclear Factor kappa B) pathways were the most discriminating pathways associated with inflammation-related MDD. These signaling pathways were processed in composite z-scores of gene expression that were used as biomarkers in regression analyses. Results showed that these transcriptomic biomarkers highly predicted depressive symptom intensity at baseline and their remission after bariatric surgery. While inflammation was present in all patients, GR signaling overactivation was found only in depressed ones where it may further increase inflammatory and apoptosis pathways. In conclusion, using an original model of inflammation-related depression and its remission without antidepressants, we provide molecular predictors of inflammation-related MDD and new insights in the molecular pathways involved.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funds from the French National Research Agency, ANR (ANR-11-JSV1-0006, LC), and the Fondation pour la Recherche Medicale (DPP20151033943, LC). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local Committee for the Protection of Persons (Bordeaux,France)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall the data are in supplemental material ER -